Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Tony S Mok, MD, FRCPC, FASCO
Videos
Lorlatinib Continues to Show Benefit as First-Line Treatment for Advanced ALK+ Non-Small Cell Lung Cancer
06/22/2026
Tony S. Mok, MD, FRCPC, FASCO
Tony S Mok, MD, FRCPC, FASCO, discusses the 7-year update from the phase 3 CROWN trial evaluating first-line lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer. The study previously demonstrated a...
Tony S Mok, MD, FRCPC, FASCO, discusses the 7-year update from the phase 3 CROWN trial evaluating first-line lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer. The study previously demonstrated a...
Tony S Mok, MD, FRCPC, FASCO,...
06/22/2026
Oncology
Joel Neal, MD
Videos
Amivantamab Plus Lazertinib Improves Survival in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer
06/18/2026
Joel Neal, MD
Joel Neal, MD, discusses updated results from CHRYSALIS-2 Cohort C evaluating first-line amivantamab plus lazertinib in patients with atypical EGFR-mutated advanced NSCLC.
Joel Neal, MD, discusses updated results from CHRYSALIS-2 Cohort C evaluating first-line amivantamab plus lazertinib in patients with atypical EGFR-mutated advanced NSCLC.
Joel Neal, MD, discusses updated...
06/18/2026
Oncology
Jamie Chaft, MD
Videos
Adjuvant Nivolumab Fails to Improve DFS Regardless of PD-L1 Status in Non-Small Cell Lung Cancer
06/10/2026
Jamie Chaft, MD
Jamie Chaft, MD, discusses results from the phase 3 EA5142 trial, part of the National Cancer Institute’s ALCHEMIST program, evaluating adjuvant nivolumab in patients with resected EGFR or ALK-negative NSCLC following standard therapy.
Jamie Chaft, MD, discusses results from the phase 3 EA5142 trial, part of the National Cancer Institute’s ALCHEMIST program, evaluating adjuvant nivolumab in patients with resected EGFR or ALK-negative NSCLC following standard therapy.
Jamie Chaft, MD, discusses...
06/10/2026
Oncology
Lyudmila Bazhenova, MD
Videos
Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer
05/12/2026
Lyudmila Bazhenova, MD
Lyudmila Bazhenova, MD, discusses results from the TRUST-I and TRUST-II trials assessing taletrectinib in ROS1-positive non-small cell lung cancer.
Lyudmila Bazhenova, MD, discusses results from the TRUST-I and TRUST-II trials assessing taletrectinib in ROS1-positive non-small cell lung cancer.
Lyudmila Bazhenova, MD,...
05/12/2026
Oncology
Lyudmila Bazhenova, MD
Videos
Taletrectinib Demonstrates Long-Term Durability in ROS1-Positive Non-Small Cell Lung Cancer
05/04/2026
Lyudmila Bazhenova, MD
Lyudmila Bazhenova, MD, discusses updated results from the TRUST-I and TRUST-II trials assessing taletrectinib in TKI-naive patients with ROS1-positive non-small cell lung cancer.
Lyudmila Bazhenova, MD, discusses updated results from the TRUST-I and TRUST-II trials assessing taletrectinib in TKI-naive patients with ROS1-positive non-small cell lung cancer.
Lyudmila Bazhenova, MD,...
05/04/2026
Oncology
Estelamari Rodriguez, MD
Videos
Perioperative Immunotherapy for Patients With Resectable Non-Small Cell Lung Cancer
03/15/2026
Estelamari Rodriguez, MD, MPH
Estelamari Rodriguez, MD, discusses the importance of continuing immunotherapy after surgery to maintain immune activation and reduce recurrence risk in patients with early-stage resectable non-small cell lung cancer.
Estelamari Rodriguez, MD, discusses the importance of continuing immunotherapy after surgery to maintain immune activation and reduce recurrence risk in patients with early-stage resectable non-small cell lung cancer.
Estelamari Rodriguez, MD,...
03/15/2026
Oncology
Kelsey Pan, MD
Videos
Defining the Optimal Immunotherapy Strategy in Resectable Non-Small Cell Lung Cancer
03/14/2026
Kelsey Pan, MD
Kelsey Pan, MD, discusses whether a neoadjuvant-only immunotherapy approach may be sufficient for patients with resectable non-small cell lung cancer.
Kelsey Pan, MD, discusses whether a neoadjuvant-only immunotherapy approach may be sufficient for patients with resectable non-small cell lung cancer.
Kelsey Pan, MD, discusses...
03/14/2026
Oncology
Corey Langer, MD, Abramson Cancer Center
Videos
Treatment Selection for ALK-Positive Metastatic Non-Small Cell Lung Cancer
09/04/2025
Corey J. Langer, MD, FACP
Corey Langer, MD, presents a case demonstrating how liquid biopsy identified an ALK fusion and guided treatment with alectinib, resulting in durable disease control and preserved quality of life in an older patient with metastatic non-small...
Corey Langer, MD, presents a case demonstrating how liquid biopsy identified an ALK fusion and guided treatment with alectinib, resulting in durable disease control and preserved quality of life in an older patient with metastatic non-small...
Corey Langer, MD, presents a...
09/04/2025
Oncology
David Spigel, MD, Sarah Cannon Research Institute
Videos
Molecular Assay May Predict Patients With Non-Small Cell Lung Cancer to Benefit From Adjuvant Therapy
06/16/2025
David Spigel, MD
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the...
06/16/2025
Oncology Learning Network APP Institute
Joshua Sabari, MD
Videos
Zongertinib for Previously Treated Patients With HER2-Mutant Advanced Non-Small Cell Lung Cancer
05/22/2025
Joshua Sabari, MD
Joshua Sabari, MD, discusses results from the phase 1a/1b Beamion LUNG-1 trial evaluating zongertinib among previously treated patients with HER2-mutant advanced non-small cell lung cancer.
Joshua Sabari, MD, discusses results from the phase 1a/1b Beamion LUNG-1 trial evaluating zongertinib among previously treated patients with HER2-mutant advanced non-small cell lung cancer.
Joshua Sabari, MD, discusses...
05/22/2025
Oncology

Recent News

FDA Approval
FDA Approves Neoadjuvant/Adjuvant Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer
10/03/2024
Stephanie Holland
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the...
10/03/2024
Oncology
News
Phase 3 IMpactMF Trial of Imetelstat Discontinued After Unfavorable Overall Survival Assessment
10/30/2026
Emily Estrada
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
The phase 3 IMpactMF trial of...
10/30/2026
Oncology
News
Cosibelimab Receives NCCN Category 2A Recommendation for Locally Advanced Cutaneous Squamous Cell Carcinoma
10/30/2026
Emily Estrada
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include...
10/30/2026
Oncology
News
Petosemtamab Plus Pembrolizumab Significantly Improves Overall Survival in Patients With Head and Neck Squamous Cell Carcinoma
10/30/2026
Emily Estrada
Results from the phase 3 LiGeR-HN1 trial demonstrated that petosemtamab plus pembrolizumab significantly improved overall survival and objective response compared with pembrolizumab alone in patients with PD-L1-positive recurrent or...
Results from the phase 3 LiGeR-HN1 trial demonstrated that petosemtamab plus pembrolizumab significantly improved overall survival and objective response compared with pembrolizumab alone in patients with PD-L1-positive recurrent or...
Results from the phase 3...
10/30/2026
Oncology
News
Relacorilant Plus Nab-Paclitaxel and Bevacizumab Demonstrates 59% Response Rate in Platinum-Resistant Ovarian Cancer
10/30/2026
Stephanie Holland
Results from the phase 2 BELLA trial demonstrated encouraging progression-free survival and response with relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer, with more pronounced activity among...
Results from the phase 2 BELLA trial demonstrated encouraging progression-free survival and response with relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer, with more pronounced activity among...
Results from the phase 2 BELLA...
10/30/2026
Oncology
News
Updated ASTRO Guidelines Expand Role of Hypofractionated Radiotherapy in Localized Prostate Cancer
10/30/2026
Stephanie Holland
Updated ASTRO clinical practice guidelines recommend moderate hypofractionated radiotherapy over conventional fractionation across all localized prostate cancer risk groups and expand the role of ultrahypofractionation, including stereotactic...
Updated ASTRO clinical practice guidelines recommend moderate hypofractionated radiotherapy over conventional fractionation across all localized prostate cancer risk groups and expand the role of ultrahypofractionation, including stereotactic...
Updated ASTRO clinical practice...
10/30/2026
Oncology
News
Real-World Study Demonstrates Clinical Activity of Lurbinectedin in Previously Treated Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz...
10/28/2026
Oncology
News
NETSARC+ Study Identifies Tumor Location and Size as Prognostic Factors in Patients With Desmoid Tumors
10/28/2026
Emily Estrada
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+...
10/28/2026
Oncology
News
G-CSF Prophylaxis Reduces Incidence of Febrile Neutropenia Without Compromising Chemoimmunotherapy Outcomes in Patients With Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter,...
10/28/2026
Oncology
News
Tambotatug Pelitecan Significantly Improves Overall Survival in Patients With Relapsed Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3...
10/28/2026
Oncology
News
Oral Hypomethylating Agents Show Comparable Hematologic Toxicity to Intravenous Therapy in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia
10/28/2026
Emily Estrada
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter...
10/28/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use